Nivolumab plus chemotherapy in patients with HER2-negative, previously untreated, unresectable, advanced, or recurrent gastric/gastroesophageal junction cancer: 3-year follow-up of the ATTRACTION-4 randomized, double-blind, placebo-controlled, phase
Authors
Li‐Yuan Bai (ORCID: https://orcid.org/0000-0001-7739-4077)
Yoon‐Koo Kang (ORCID: https://orcid.org/0000-0003-0783-6583)
Narikazu Boku (ORCID: https://orcid.org/0000-0002-1438-707X)
Sun Jin Sym (ORCID: https://orcid.org/0000-0002-1340-6291)
Nivolumab plus chemotherapy in patients with HER2-negative, previously untreated, unresectable, advanced, or recurrent gastric/gastroesophageal junction cancer: 3-year follow-up of the ATTRACTION-4 randomized, double-blind, placebo-controlled, phase
Li‐Yuan Bai, Yoon‐Koo Kang, Narikazu Boku, Sun Jin Sym et al.
Citations
29 citations
Journal
Gastric Cancer
Topics
Gastric Cancer Management and Outcomes
Field-Weighted Citation Impact (FWCI)
12.15
article
Nivolumab plus chemotherapy in patients with HER2-negative, previously untreated, unresectable, advanced, or recurrent gastric/gastroesophageal junction cancer: 3-year follow-up of the ATTRACTION-4 randomized, double-blind, placebo-controlled, phase
Li‐Yuan Bai, Yoon‐Koo Kang, Narikazu Boku, Sun Jin Sym, Kohei Shitara, Kunihiro Tsuji, Sun Young Rha, Keun-Wook Lee, Eiji Nishiyama, Shigenori Kadowaki, Jen‐Shi Chen, Do‐Youn Oh, Sang Cheul Oh, Ken Kato, Min‐Hee Ryu, Kensei Yamaguchi, Li‐Tzong Chen, Ik‐Joo Chung, Takeshi Omori, Takashi Nakada, Shunsuke Hagihara, Reina Makino, Shinichi Sakuramoto
article en
29 citations
Abstract
No abstract available for this paper.
Publication Tag
Gastric CancerVol. 27(6)
Institutions
Ulsan College (KR), Kaohsiung Medical University (TW), Tokyo University of Science (JP), National Health Research Institutes (TW), Chang Gung University (TW), China Medical University (TW), Korea University (KR), Asan Medical Center (KR), Seoul National University Hospital (KR), Seoul National University Bundang Hospital (KR), University of Ulsan (KR), Gachon University Gil Medical Center (KR), Ono Pharmaceutical (Japan) (JP), Linkou Chang Gung Memorial Hospital (TW), Ishikawa Prefectural Central Hospital (JP), China Medical University Hospital (TW), Aichi Cancer Center (JP), The Cancer Institute Hospital (JP), National Cancer Center Hospital East (JP), Chonnam National University Hwasun Hospital (KR), Osaka International Cancer Institute (JP), National Cheng Kung University Hospital (TW), Yonsei University Health System (KR), Japanese Foundation For Cancer Research (JP), Saitama Medical University (JP)